Cemhan Biricik, CEO of Fast Lab Technologies, and Martin Perlin, its medical director, are alleged to have billed public and private payors for testing that was never done.

The laboratory medicine organization is focused on the benefits of using data science within laboratories to more effectively care for patients and track utilization.

The firm expects to see growth in its life science business, in particular after it showed positive signs during the second quarter.

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming nonetheless, and the industry should play a lead role in developing them.

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus on existing disease areas.

The new BD Onclarity HPV test would enable patients to collect a sample without the need for liquids or other devices and mail it to the laboratory for testing.